Overview
Announcements

Ordinary Adjustment | Solactive China Healthcare Disruption Index | Effective Date 3rd March 2025

Solactive China Healthcare Disruption Index:

In the ordinary adjustment, the following composition will be implemented effective open 3rd March 2025:

AKESO INC
ALIBABA HEALTH INFORMATION TECHNOLOGY LTD
ALPHAMAB ONCOLOGY
ASCLETIS PHARMA INC
CHINA MEDICAL SYSTEM HOLDINGS LTD
CHINA RESOURCES PHARMACEUTICAL
CSPC PHARMACEUTICAL GROUP LTD
GENSCRIPT BIOTECH CORP
GRAND PHARMACEUTICAL GROUP LTD
HANSOH PHARMACEUTICAL GROUP CO
HBM HOLDINGS LTD
HUTCHMED CHINA LTD
INNOVENT BIOLOGICS INC
KANGJI MEDICAL HOLDINGS LTD
KEYMED BIOSCIENCES INC
LEPU BIOPHARMA CO LTD-H
LIVZON PHARMACEUTICAL GROUP INC
LUYE PHARMA GROUP LTD
PHARMARON BEIJING CO LTD-H
REMEGEN CO LTD-H
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD
SHANGHAI HENLIUS BIOTECH INC
SHANGHAI JUNSHI BIOSCIENCES CO LTD
SHANGHAI MICROPORT MEDBOT GR
SHANGHAI PHARMACEUTICALS HOLDING CO LTD-H
SIHUAN PHARMACEUTICAL HLDGS GRP ORD
SIMCERE PHARMACEUTICAL GROUP
SINO BIOPHARMACEUTICAL LTD ORD
SKB BIO-B ORD H
WUXI APPTEC CO LTD
WUXI BIOLOGICS CAYMAN INC
YICHANG HEC CHANGJIANG PHA-H
ZAI LAB LTD